![](../../files/images/goods/299-88-7.png)
Dibenzoyl Thiamine
CAS No. 299-88-7
Dibenzoyl Thiamine ( Bentiamine )
Catalog No. M21353 CAS No. 299-88-7
Dibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.
Purity : >98% (HPLC)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
Size | Price / USD | Stock | Quantity |
100MG | 45 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameDibenzoyl Thiamine
-
NoteResearch use only not for human use.
-
Brief DescriptionDibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.
-
DescriptionDibenzoyl Thiamine a lipophilic derivative of vitamin B (thiamine) is a kind of food additive.
-
SynonymsBentiamine
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number299-88-7
-
Formula Weight490.6
-
Molecular FormulaC26H26N4O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO:98 mg/mL (199.76 mM)
-
SMILESCC1=NC=C(C(=N1)N)CN(C=O)/C(=C(/CCOC(=O)C2=CC=CC=C2)\SC(=O)C3=CC=CC=C3)/C
-
Chemical NameBenzenecarbothioic acid S-(2-(((4-amino-2-methyl-5-pyrimidinyl)methyl)formylamino)-1-(2-(benzoyloxy)ethyl)-1-propenyl) ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
![](/themes/theme/en/images/ct.png)
![](/themes/theme/en/images/ct2.png)
-
Ofatumumab
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation.
-
GIP (1-39)
Endogenous truncated form of the incretin hormone GIP. More potent at stimulating glucose-dependent insulin secretion from rat pancreatic β-cells than GIP.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?